Results 141 to 150 of about 2,479 (207)

Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis. [PDF]

J Headache Pain
Romozzi M, Palermo M, Danno D, Katsuki M, Tosto F, Signorelli F, Vollono C, Matsumori Y, Calabresi P, Ornello R, Iannone LF.   +10 more
europepmc   +1 more source

Potential drug interaction between calcitonin gene-related peptide antagonists and neonatal Fc receptor inhibitors. [PDF]

Headache
Harlan A, Weber K.
europepmc   +1 more source

Patient Preferences for Self-Injectable Preventive Treatment for Migraine: A Multi-country Discrete Choice Experiment. [PDF]

Neurol Ther
Seo J, Thomas C, Tervonen T, Krucien N, Ford JH, Stauffer VL, Nicholson RA, Duffy KH, Tockhorn-Heidenreich A.   +8 more
europepmc   +1 more source

Substance P release from rat dura mater is inversely correlated with CGRP release- experiments using glycerol trinitrate and anti-CGRP antibodies. [PDF]

J Headache Pain
Dux M, Messlinger K.
europepmc   +1 more source

Health care resource utilization and direct costs incurred over 12 months by patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibodies: A US real-world study. [PDF]

J Manag Care Spec Pharm
Varnado OJ, Brady B, Zagar A, Robles Y, Ó Céilleachair A, Hoyt M.   +5 more
europepmc   +1 more source

CGRP and Migraine: Real-World Insights and Future Therapeutic Directions. [PDF]

Annu Rev Med
Russo AF, Kaiser EA.
europepmc   +1 more source

Effect of Biological Therapy on Symptom Burden and Functional Disability in Patients with Migraine: A Before-and-After Analysis. [PDF]

Zdr Varst
Ličina A, Fabjan A, Žibert J, Kamenšek T.   +3 more
europepmc   +1 more source

CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review. [PDF]

Neurology
Eller MT, Schwarzová K, Gufler L, Karisik A, Kaltseis K, Frank F, Broessner G.   +6 more
europepmc   +1 more source

The Effect of Fremanezumab on Pain in Patients with Complex Regional Pain Syndrome: Study Protocol of a Randomized, Double-Blind, Proof-of-Concept, Placebo-Controlled Trial. [PDF]

Brain Sci
Thiyagarajah A, Terkelsen AJ, Birklein F, Finnerup NB, Gylfadottir SS.   +4 more
europepmc   +1 more source

Real-World Lessons with Fremanezumab as the Third Available CGRP Monoclonal Antibody in a Third-Level Hospital: Focus on the Factors Predicting Response. [PDF]

J Clin Med
Polanco M, Gárate G, Sánchez-Gudín J, Madera J, Pascual J, González-Quintanilla V.   +5 more
europepmc   +1 more source